Arthritis is the second leading cause of medical discharge from the U.S. Army following only battlefield wounds, and carries with it enormous physical, financial, and societal costs for servicemembers and veterans. In fact, arthritis-related health care costs and loss of earning due to disability from arthritis totaled approximately $303.5 billion in 2013.[1]

The ACR applauds Congress for reappropriating $10million in funding for dedicated arthritis research at the Department of Defense through the Congressionally Directed Medical Research Program (CDMRP) following the defunding of the program in 2025.

Stable, dedicated funding for arthritis research is critical to advance progress on arthritis risks, outcomes, and treatments among service members. Arthritis research funding through the CDMRP also helps to prevent unwanted medical discharges and mitigates the effects of arthritis on military service. Advances made through research funded by the CDMRP will also benefit civilians living with rheumatic disease.

To enhance our military readiness and lessen the impact of arthritis on servicemembers and veterans, the ACR urges Congress to continue funding arthritis research in the CDMRP at least $10 million to accelerate arthritis prevention strategies and treatment breakthroughs for our military. Take a moment to contact your lawmakers today!

[1] Murphy LB, et al. Arthritis. 70, no 6, 2018:869- 876.